Cargando…
P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
Autores principales: | Shah, Bijal, Cassaday, Ryan D., Park, Jae H., Houot, Roche, Oluwole, Olalekan O., Logan, Aaron C., Boissel, Nicolas, Leguay, Thibaut, Bishop, Michael R., Topp, Max S., O’dwyer, Kristen M., Baer, Maria R., Schiller, Gary J., Abedi, Mehrdad, Minnema, Monique C., Stiff, Patrick, Zhou, Lang, Hadjivassileva, Tsveta, Damico Khalid, Rita, Ghobadi, Armin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428477/ http://dx.doi.org/10.1097/01.HS9.0000968380.54499.e3 |
Ejemplares similares
-
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023) -
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
por: Shah, Bijal D., et al.
Publicado: (2022) -
Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023) -
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022) -
Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia
Publicado: (2023)